Salarius Pharmaceuticals Inc (NAS:SLRX)
$ 1.54 0.09 (6.21%) Market Cap: 2.22 Mil Enterprise Value: -2.17 Mil PE Ratio: 0 PB Ratio: 0.42 GF Score: 31/100

Q4 2020 Salarius Pharmaceuticals Inc Earnings Call Transcript

Mar 18, 2021 / 08:30PM GMT
Release Date Price: $300 (-5.06%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Salarius Pharmaceuticals Q4 and Year-end 2020 Financial Results Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your host, Jason Rando with Tiberend Strategic Advisors. Sir, please go ahead.

Jason Rando
Tiberend Strategic Advisors, Inc. - COO & EVP

Good afternoon, everyone, and thank you for joining Salarius Pharmaceuticals 2020 Fourth Quarter and Full Year Financial and Corporate Results Call. Earlier this afternoon, Salarius Pharmaceuticals issued a press release detailing its financial results for the 3 months and the full year ended December 31, 2020, which we encourage listeners to read. The press release can be found in the News section of salariuspharma.com. Salarius also filed a 10-K this afternoon, which is available on Salariuspharma.com and sec.gov.

Before beginning today's call, I would like to make the following statement. Today, we'll be making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot